People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Other, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sequenta, Inc. | — | Other | Series B | $44.9M | $332.3M | 2009 |
| Boreal Genomics Inc. | — | Biotechnology | Series B | $24.5M | $714.4M | 2010 |
| OspreyData Inc. | — | Other Technology | Series A | $9.6M | $93.3M | 2016 |
Thomas Willis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Willis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Burke | 1 | 14 |
| Keith Crandell | 1 | 11 |
| Stuart Frost | 1 | 10 |
| Rowan Chapman | 1 | 7 |
| Mike Murphy | 1 | 7 |
| Nicholas Naclerio | 1 | 5 |
| Bill Ericson | 1 | 5 |
| Jim Tananbaum | 1 | 4 |
| John Stuelpnagel | 1 | 3 |
| Malek Faham | 1 | 3 |
| Miles Mahoney | 1 | 3 |
| Caley Castelein | 1 | 2 |
| Michael Colaco | 1 | 2 |
| Larry Sheakley | 1 | 2 |
| Jacob Goldfield | 1 | 2 |
| NITIN SOOD | 1 | 1 |
| ANDREA MARZIALI | 1 | 1 |
| Keith Crandall | 1 | 1 |
| Karen Kirk | 1 | 1 |
| Andre Marziali | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.